NASDAQ:LUCD Lucid Diagnostics (LUCD) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free LUCD Stock Alerts $0.67 -0.01 (-1.47%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.63▼$0.6850-Day Range$0.67▼$1.3652-Week Range$0.63▼$1.85Volume235,339 shsAverage Volume218,993 shsMarket Capitalization$32.33 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Lucid Diagnostics alerts: Email Address Lucid Diagnostics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside310.4% Upside$2.75 Price TargetShort InterestHealthy2.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.13 out of 5 starsMedical Sector539th out of 908 stocksSurgical & Medical Instruments Industry63rd out of 98 stocks 3.5 Analyst's Opinion Consensus RatingLucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLucid Diagnostics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.53% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lucid Diagnostics has recently decreased by 18.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLucid Diagnostics does not currently pay a dividend.Dividend GrowthLucid Diagnostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUCD. Previous Next 0.8 News and Social Media Coverage News SentimentLucid Diagnostics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lucid Diagnostics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for LUCD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Lucid Diagnostics is held by insiders.Percentage Held by Institutions74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Lucid Diagnostics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lucid Diagnostics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Lucid Diagnostics Stock (NASDAQ:LUCD)Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Read More LUCD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUCD Stock News HeadlinesApril 21, 2024 | nasdaq.comLucid Diagnostics Inc. Common Stock (LUCD)April 19, 2024 | investorplace.com3 Penny Stocks That Could Make a Big Comeback by the End of Q2April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 15, 2024 | markets.businessinsider.comLucid Diagnostics: Strong Buy Rating with Significant Market Potential Despite Near-Term LossesApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lucid Diagnostics Amidst Strong EsoGuard Testing Growth and Clear Reimbursement PathApril 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)April 10, 2024 | investing.comLucid Diagnostics holds Buy rating, and stock target on company's performanceMarch 28, 2024 | seekingalpha.comLucid Diagnostics Inc. (LUCD) Q4 2023 Earnings Call TranscriptApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.March 28, 2024 | markets.businessinsider.comBuy Rating for Lucid Diagnostics: Solid Test Volumes and Strategic Growth Initiatives Propel Market PositionMarch 28, 2024 | finance.yahoo.comPAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lucid Diagnostics Amid Strong Financials and Strategic Growth InitiativesMarch 27, 2024 | finanznachrichten.dePAVmed Inc.: PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial ResultsMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lucid Diagnostics Amidst Growing Test Volume and Strategic Positioning for Medicare ReimbursementMarch 27, 2024 | finance.yahoo.comLucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comQ4 2023 Lucid Diagnostics Inc Earnings CallMarch 25, 2024 | investorplace.comLUCD Stock Earnings: Lucid Diagnostics Beats EPS, Misses Revenue for Q4 2023March 25, 2024 | finance.yahoo.comLucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial ResultsMarch 21, 2024 | markets.businessinsider.comLucid Diagnostics Gets Positive Data From Clinical Validation Study Of EsoGuard Esophageal DNA TestMarch 21, 2024 | prnewswire.comLucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationMarch 20, 2024 | finance.yahoo.comLucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 ConferenceFebruary 21, 2024 | msn.comLucid Diagnostics target oesphageal cancer with early testingFebruary 16, 2024 | prnewswire.comLucid Diagnostics Provides Update Regarding World Trade Center Health ProgramFebruary 15, 2024 | finance.yahoo.comLucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional TestimonyFebruary 15, 2024 | prnewswire.comLucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional TestimonyFebruary 8, 2024 | finanznachrichten.deLucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and SurvivorsDecember 30, 2023 | benzinga.comLucid Diagnostics Stock (NASDAQ:LUCD) Dividends: History, Yield and DatesSee More Headlines Receive LUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LUCD CUSIPN/A CIK1799011 Webwww.luciddx.com Phone212-949-4319FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$3.00 Low Stock Price Target$2.50 Potential Upside/Downside+310.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,670,000.00 Net Margins-2,169.07% Pretax Margin-2,169.11% Return on Equity-901.79% Return on Assets-121.11% Debt Debt-to-Equity RatioN/A Current Ratio0.75 Quick Ratio0.74 Sales & Book Value Annual Sales$2.43 million Price / Sales13.30 Cash FlowN/A Price / Cash FlowN/A Book Value($0.47) per share Price / Book-1.43Miscellaneous Outstanding Shares48,240,000Free Float45,929,000Market Cap$32.33 million OptionableNo Data Beta1.63 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Lishan Aklog M.D. (Age 58)Chairman & CEO Mr. Shaun M. O'Neill M.B.A. (Age 41)President & COO Mr. Dennis M. McGrath CPA (Age 67)Chief Financial Officer Dr. Sanford D. Markowitz M.D.Ph.D., Cofounder & Strategic Advisor, Member of the Medical Advisor BoardDr. Joseph Willis M.D.Cofounder, Strategic Advisor & Member of Medical Advisory BoardDr. Amitabh Chak M.D.Cofounder, Strategic Advisor & Member of Medical Advisory BoardRichard D. YazbeckChief Technology OfficerDr. Suman M. Verma M.D.Ph.D., Chief Scientific OfficerDr. Brian J. deGuzman M.D. (Age 59)Chief Compliance Officer Mr. Michael Adam Gordon (Age 50)General Counsel & Secretary More ExecutivesKey CompetitorsModular MedicalNASDAQ:MODDCo-DiagnosticsNASDAQ:CODXLENSARNASDAQ:LNSRSpectral AINASDAQ:MDAINeuroOne Medical TechnologiesNASDAQ:NMTCView All CompetitorsInsidersStanley LapidusSold 200 sharesTotal: $286.00 ($1.43/share)Stanley LapidusSold 3,817 sharesTotal: $5,534.65 ($1.45/share)View All Insider Transactions LUCD Stock Analysis - Frequently Asked Questions Should I buy or sell Lucid Diagnostics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LUCD shares. View LUCD analyst ratings or view top-rated stocks. What is Lucid Diagnostics' stock price target for 2024? 2 Wall Street research analysts have issued 1 year target prices for Lucid Diagnostics' stock. Their LUCD share price targets range from $2.50 to $3.00. On average, they predict the company's stock price to reach $2.75 in the next twelve months. This suggests a possible upside of 310.4% from the stock's current price. View analysts price targets for LUCD or view top-rated stocks among Wall Street analysts. How have LUCD shares performed in 2024? Lucid Diagnostics' stock was trading at $1.41 at the beginning of the year. Since then, LUCD shares have decreased by 52.5% and is now trading at $0.6701. View the best growth stocks for 2024 here. Are investors shorting Lucid Diagnostics? Lucid Diagnostics saw a drop in short interest in April. As of April 15th, there was short interest totaling 361,400 shares, a drop of 18.0% from the March 31st total of 441,000 shares. Based on an average trading volume of 164,900 shares, the short-interest ratio is presently 2.2 days. Currently, 2.5% of the company's stock are sold short. View Lucid Diagnostics' Short Interest. When is Lucid Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our LUCD earnings forecast. How were Lucid Diagnostics' earnings last quarter? Lucid Diagnostics Inc. (NASDAQ:LUCD) posted its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.26) earnings per share (EPS) for the quarter. The business earned $1.04 million during the quarter. Lucid Diagnostics had a negative net margin of 2,169.07% and a negative trailing twelve-month return on equity of 901.79%. During the same quarter in the prior year, the business posted ($0.22) earnings per share. When did Lucid Diagnostics IPO? Lucid Diagnostics (LUCD) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Lucid Diagnostics? Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LUCD) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
